Cara Therapeutics reported $0 in Loan Capital for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Loan Capital Change
Acadia Pharmaceuticals ACAD:US $ 0M 0M
Acelrx Pharmaceuticals ACRX:US $ 9.37M 1.89M
Aerie Pharmaceuticals AERI:US $ 222.02M 5.94M
Antares Pharma ATRS:US $ 3.34M 11.43M
Arena Pharmaceuticals ARNA:US $ 38.78M 1.25M
Cara Therapeutics CARA:US $ 0 0
Endo International Ordinary Shares ENDP:US $ 8074.44M 26.54M
Halozyme Therapeutics HALO:US $ 785.57M 0.84M
Horizon Pharma HZNP:US $ 2560.44M 2.07M
JAZZ PHA JAZZ:US $ 6495.33M 4642.3M
Johnson & Johnson JNJ:US $ 30310M 47M
Neurocrine Biosciences NBIX:US $ 326.3M 4.3M
Pacira Pharmaceuticals PCRX:US $ 321.71M 4.37M
Pain Therapeutics PTIE:US $ 0M 0M
Redhill Biopharma RDHL:US $ 86.14M 0.22M
Revance Therapeutics RVNC:US $ 280M 0.31M
Supernus Pharmaceuticals SUPN:US $ 370.38M 14.15M
Teva Pharmaceutical Industries TEVA:US $ 21602M 686M
Vanda Pharmaceuticals VNDA:US $ 0M 0M